🔍 Definition
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fracture. Per the NIH Osteoporosis and Related Bone Diseases National Resource Center, osteoporosis is often called a “silent disease” because bone loss occurs without symptoms until a fracture occurs.
The International Osteoporosis Foundation (IOF) estimates that osteoporosis affects approximately 200 million women worldwide and causes more than 8.9 million fractures annually. In the United States, the NIH estimates that 10 million Americans have osteoporosis and another 44 million have low bone density.
Diagnostic criteria per the World Health Organization (WHO) are based on dual-energy X-ray absorptiometry (DXA) T-score measurement:
- Normal: T-score ≥ −1.0
- Osteopenia (low bone mass): T-score between −1.0 and −2.5
- Osteoporosis: T-score ≤ −2.5 at the lumbar spine, femoral neck, or total hip
- Severe osteoporosis: T-score ≤ −2.5 plus one or more fragility fractures (independent of T-score threshold)
Clinically, osteoporosis is also diagnosed when a fragility (low-trauma) fracture occurs — a fracture resulting from mechanical forces that would not normally cause fracture, such as a fall from standing height or less, regardless of the T-score value, per National Osteoporosis Foundation (NOF) guidelines.
🗂️ Alternative Terminology
| Formal / ICD-10-CM Term | Colloquial / Lay / Clinical Aliases |
|---|---|
| Age-related osteoporosis (M81.0) | Senile osteoporosis; postmenopausal osteoporosis (female); involutional osteoporosis; primary osteoporosis Type I/II |
| Osteoporosis with current pathological fracture (M80.x) | Osteoporotic fracture; fragility fracture; low-trauma fracture; insufficiency fracture; pathologic fracture on osteoporosis background |
| Other osteoporosis without current pathological fracture (M81.8) | Secondary osteoporosis; drug-induced osteoporosis; steroid-induced osteoporosis; disuse osteoporosis |
| Localized osteoporosis [Lequesne] (M81.6) | Regional osteoporosis; Lequesne’s syndrome; transient osteoporosis of the hip |
| Osteopenia | Low bone density; low bone mass; pre-osteoporosis; reduced bone mineral density (BMD) |
| Vertebral compression fracture (VCF) | Vertebral crush fracture; wedge fracture of spine; spinal compression fracture |
| Hip fracture (osteoporotic) | Femoral neck fracture; intertrochanteric fracture; subcapital fracture; broken hip |
| Fragility fracture of wrist | Colles’ fracture (distal radius); wrist fracture in older adult |
| DEXA / DXA scan | Bone density test; bone densitometry; bone mineral density (BMD) test |
| Fracture FRAX risk assessment | 10-year fracture probability; FRAX score; fracture risk calculator |
🩺 Signs & Symptoms
Osteoporosis is largely asymptomatic until a fracture occurs. When signs and symptoms are present, they typically reflect complications of bone fragility. Coders and CDI specialists should recognize the following clinical presentations that may prompt documentation queries:
- Vertebral compression fracture: Acute or chronic back pain (thoracic or lumbar), loss of height (≥ 2 cm), kyphosis (“dowager’s hump”), restricted mobility, possible radiculopathy if nerve root compression occurs.
- Hip fracture: Inability to bear weight, hip or groin pain, shortened and externally rotated limb, swelling or bruising at the hip.
- Wrist / Colles’ fracture: Pain, swelling, deformity at the distal forearm following low-energy fall on outstretched hand.
- Other fragility fractures: Rib fractures from minimal trauma (coughing, sneezing), humerus fractures, pelvic fractures — all in the absence of high-energy mechanisms.
- Chronic pain: Persistent back pain from healed or healing vertebral fractures; chronic musculoskeletal pain reducing functional status.
- Postural changes: Progressive thoracic kyphosis, loss of height over time, protruding abdomen from spinal deformity.
- Fear of falling: Psychological impact reducing ambulation and activity, contributing to deconditioning and fall risk.
Osteoporosis itself (M81.0/M81.8) does NOT generate symptoms — the fracture does. When a provider documents both “osteoporosis” and “vertebral fracture” or “hip fracture,” the correct code is from M80 (osteoporosis WITH current pathological fracture), not M81 + a separate fracture code. This distinction is critical for HCC risk adjustment and accurate DRG assignment.
🧭 Differential Diagnosis
| Condition | Key Distinguishing Features | Relevant ICD-10-CM |
|---|---|---|
| Osteopenia (low bone mass) | T-score −1.0 to −2.5; no fracture; not coded as osteoporosis — document BMD finding | M85.80–M85.89 (other specified disorders of bone density) |
| Osteomalacia | Defective bone mineralization (vitamin D/calcium deficiency); pain, proximal muscle weakness; Looser zones on imaging; distinguished from osteoporosis by bone histology and labs | M83.x (adult osteomalacia); E55.9 (vitamin D deficiency) |
| Paget’s disease of bone | Focal bone remodeling disorder; elevated ALP; mosaic bone pattern on biopsy; predilection for pelvis, skull, femur, tibia; often incidental finding | M88.x |
| Multiple myeloma / metastatic bone disease | Lytic lesions on imaging; hypercalcemia; SPEP/serum free light chains abnormal; pathologic fracture in neoplastic disease coded separately | M84.5xx (pathologic fracture in neoplastic disease); C90.0x (multiple myeloma) |
| Primary hyperparathyroidism | Elevated PTH and calcium; subperiosteal bone resorption; osteitis fibrosa cystica in severe cases; can cause secondary osteoporosis | E21.0–E21.3 |
| Renal osteodystrophy | Associated with CKD; mixed pattern (high/low turnover); requires CKD diagnosis | N25.0; N18.3–N18.6 |
| Traumatic fracture (vs. pathologic) | High-energy mechanism; no underlying bone disease; coded with S-codes (injury chapter) | S12–S32 (spine); S72 (hip/femur); S52 (forearm) |
| Stress fracture (fatigue fracture) | Repetitive mechanical loading (athletes, military); normal bone; absence of metabolic bone disease | M84.3xx (stress fracture) |
| Pathologic fracture NEC (non-osteoporotic) | Fracture in other disease (e.g., osteogenesis imperfecta); not due to osteoporosis specifically | M84.4xx (pathologic fracture NEC); M84.6xx (in other disease) |
| Cushing’s syndrome | Hypercortisolism; central obesity, striae, moon face, proximal myopathy; can cause secondary osteoporosis | E24.0–E24.9 |
Vertebral fracture: traumatic vs. pathologic. A vertebral compression fracture in an elderly patient is frequently osteoporotic (pathologic, M80.08X- when documented as vertebra[e]) but may be coded as a traumatic fracture (S22.0-/S32.0-) when documentation supports a traumatic etiology. Clinical context (bone density, imaging characteristics, trauma energy level) determines the correct code family. CDI specialists should query when documentation is ambiguous. Coding a pathologic fracture as traumatic can result in missed severity and risk-adjustment capture.
📋 Clinical Indicators
The following clinical indicators in the medical record suggest osteoporosis and/or osteoporotic fracture, warranting documentation review or query:
| Clinical Indicator | Documentation Action | Code Impact |
|---|---|---|
| DXA T-score ≤ −2.5 reported in record | Confirm provider diagnosis of “osteoporosis” in assessment/plan | M81.0 or M80.x (if fracture present) |
| Fragility fracture (low-energy fall, minimal trauma) in patient ≥ 50 | Query: Is this a pathological fracture due to osteoporosis? | M80.x risk-adjustment category depends on fracture site and current payment model (e.g., vertebral HCC 401; hip/femur HCC 402 in the 2027 CDI Reference) |
| Vertebral compression fracture on imaging, no high-energy mechanism | Query for osteoporotic vs. traumatic vs. metastatic etiology | M80.08X- (osteoporotic pathological vertebral fracture) vs. S22/S32 (traumatic fracture) |
| Long-term corticosteroid therapy (Z79.52) + bone pain or fracture | Query for medication-induced (secondary) osteoporosis | M80.8xxA or M81.8 + Z79.52 |
| Post-menopausal female with fracture at low energy | Confirm osteoporosis diagnosis; specify age-related vs. hormonal etiology | M80.0x (age-related) + N95.1 if menopausal symptoms |
| Bisphosphonate therapy (alendronate, risedronate, zoledronic acid) | Confirms osteoporosis treatment — query for diagnosis if not documented | Z79.83 (long-term bisphosphonate use) |
| Denosumab (Prolia) administration | Confirms osteoporosis treatment; supports MEAT criteria for HCC | J0897 + M81.0 or M80.x |
| Teriparatide or abaloparatide therapy | Confirms severe/established osteoporosis — anabolic agents used in high-risk patients | J3110 for teriparatide; J3590 or payer-specific unclassified reporting for abaloparatide + M80.x or M81.0 |
| History of osteoporotic fracture (healed) | Code personal history; no longer a current fracture | Z87.310 |
| Height loss ≥ 2 cm, kyphosis, back pain in elderly | Imaging review; query for VCF; assess for osteoporosis documentation | M80.0Ax (VCF in osteoporosis) |
| Secondary causes: hyperthyroidism, hyperparathyroidism, Cushing’s, CKD, IBD, celiac, long-term steroids | Code the underlying cause + M81.8 or M80.8x | Secondary osteoporosis coding requires both codes |
Patient chart documents a DXA T-score of −2.8 at the lumbar spine, alendronate use, and a recent vertebral compression fracture. Provider problem list states “back pain” but does not explicitly document “osteoporosis.” Query the provider: Does the patient have a diagnosis of osteoporosis? If so, is this age-related (primary) or secondary osteoporosis? Is the vertebral compression fracture a pathological fracture due to osteoporosis? Capturing the osteoporosis diagnosis with current pathological vertebral fracture (M80.08XA for initial encounter when supported) enables appropriate fracture HCC capture (e.g., HCC 401 in the 2027 CDI Reference) and supports accurate clinical severity.
🦴 Anatomy & Pathophysiology
Bone is a dynamic connective tissue continuously remodeled through two coupled processes: osteoclastic bone resorption and osteoblastic bone formation. In healthy adults, these processes are in balance, maintaining bone mineral density (BMD). Per StatPearls (NCBI), osteoporosis develops when bone resorption exceeds formation, leading to net bone loss.
Bone Compartments Affected
- Trabecular (cancellous) bone: Found in vertebral bodies, femoral neck, distal radius, and ribs. Highly metabolically active; preferentially affected in early (postmenopausal) osteoporosis. Accounts for most vertebral and Colles’ fractures.
- Cortical bone: Forms the outer shell of all bones and diaphysis of long bones. Predominantly lost in age-related osteoporosis and secondary causes.
Key Pathophysiological Mechanisms
- Estrogen deficiency (postmenopausal): Estrogen inhibits osteoclast activity. Loss of estrogen at menopause accelerates bone resorption dramatically; trabecular bone loss can be 3–5% per year in the first 5–7 years post-menopause, per NOF.
- Age-related bone loss (Type II / senile): Affects both sexes after age 70. Relates to decreased osteoblast activity, reduced calcium absorption, secondary hyperparathyroidism from vitamin D deficiency, and decline in growth hormone/IGF-1 axis.
- Glucocorticoid-induced osteoporosis (GIOP): Systemic corticosteroids reduce osteoblast differentiation and proliferation, increase osteocyte and osteoblast apoptosis, impair intestinal calcium absorption, and increase renal calcium excretion. Even doses ≥ 5 mg/day prednisone equivalent for ≥ 3 months significantly increase fracture risk, per ACR guidelines.
- Secondary osteoporosis mechanisms: Hyperparathyroidism increases bone resorption via PTH-mediated osteoclast activation; hyperthyroidism accelerates bone turnover; hypogonadism (males and females) removes sex hormone protection; glucocorticoid excess and malabsorption (celiac, IBD) impair calcium/vitamin D utilization.
- RANKL/OPG pathway: The RANK/RANKL/OPG axis is the central regulatory pathway of osteoclastogenesis. Denosumab (Prolia) inhibits RANKL, preventing osteoclast formation. Bisphosphonates inhibit osteoclast function by disrupting the mevalonate pathway.
Common Fracture Sites
The classic “fragility triad” of osteoporotic fractures, per UpToDate, includes:
- Vertebral compression fractures (VCF): Most common; thoracic T7–T12 and lumbar L1–L4; often asymptomatic initially.
- Hip fracture (femoral neck / intertrochanteric): Highest morbidity and mortality; 20–30% of patients die within one year of a hip fracture, per CDC fall prevention data.
- Distal radius (Colles’) fracture: Often the earliest fragility fracture; sentinel event prompting DXA screening.
💊 Medication Impact / Treatment
Pharmacotherapy for osteoporosis should be documented with specificity in the medical record to support accurate coding, HCC capture, and prior authorization. Per Endocrine Society guidelines and the NOF, the following medication classes are used:
Antiresorptive Agents (First-line)
- Bisphosphonates (oral): Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva) — oral weekly/monthly. ICD-10 code Z79.83 (long-term bisphosphonate use) should be captured. Part D benefit for oral forms.
- Bisphosphonates (IV): Zoledronic acid (Reclast) 5 mg annual infusion — HCPCS J3489 (injection, zoledronic acid, 1 mg; 5 units for 5 mg). Ibandronate 3 mg IV quarterly — HCPCS J1740 (injection, ibandronate sodium, 1 mg; 3 units for 3 mg). Part B coverage and medical necessity depend on payer policy and setting.
- Denosumab (Prolia): 60 mg SC every 6 months; inhibits RANKL. HCPCS J0897 (injection, denosumab, 1 mg; Prolia 60 mg = 60 units when separately payable and covered). Critical documentation: Discontinuation without transitioning to another antiresorptive therapy can cause rebound vertebral fractures. Always document reason for discontinuation and follow-on therapy plan.
- Raloxifene (Evista): SERM — reduces vertebral fracture risk; no parenteral administration; oral daily. No specific HCPCS for physician administration; Part D oral.
Anabolic Agents (For High-Risk / Established Osteoporosis)
- Teriparatide (Forteo): Recombinant PTH(1-34); 20 mcg SC daily for up to 2 years. HCPCS J3110 (may apply; verify FY2026 assignment). Requires prior authorization; high cost.
- Abaloparatide (Tymlos): PTHrP analog; 80 mcg SC daily for up to 2 years. HCPCS J3484. Reduces vertebral and nonvertebral fracture risk.
- Romosozumab (Evenity): Anti-sclerostin antibody; 210 mg SC monthly for 12 months. HCPCS J3111 (injection, romosozumab-aqqg, 1 mg) is reported when separately payable and administered in the covered setting. Dual mechanism (anabolic + antiresorptive). Must transition to antiresorptive therapy after 12 months. High cardiovascular risk caveat — document MI/stroke history.
Supportive Therapies
- Calcium and Vitamin D supplementation: Foundational therapy; E55.9 (vitamin D deficiency) and E83.51 (hypocalcemia) should be coded when documented. Calcium 1,000–1,200 mg/day; Vitamin D 800–1,000 IU/day.
- Hormone therapy (HRT): Estrogen ± progestogen for postmenopausal women; reduces bone loss; FDA-approved for prevention but not as first-line for osteoporosis treatment due to breast cancer risk.
- Calcitonin (Miacalcin): Less commonly used; primarily for pain management in acute VCF.
Steroid-Induced Osteoporosis — Drug Interaction Alert
Patients on long-term systemic glucocorticoids (Z79.52) require co-prescription of bisphosphonates per ACR GIOP guidelines. Both Z79.52 and the osteoporosis diagnosis (M81.8 or M80.8xx) should be coded. Failure to document and code steroid-induced osteoporosis is a significant CDI opportunity.
Denosumab (Prolia) rebound fracture risk: When denosumab is discontinued abruptly without bridging bisphosphonate therapy, multiple vertebral fractures can occur. If a patient on denosumab experiences new vertebral fractures after discontinuation, the fractures are still coded as osteoporotic (M80.0xxA) but the medication discontinuation context should be documented by the provider. Auditors should flag records where denosumab is listed but a new fracture occurs — query for clinical context.
Preview ends here. The full guide continues with FY2027 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines
Osteoporosis codes are found in Chapter 13: Diseases of the Musculoskeletal System and Connective Tissue (M00–M99), specifically categories M80–M81, per the FY2027 ICD-10-CM Official Guidelines for Coding and Reporting. Key guidelines include:
Guideline 1: Category M80 vs. M81
- M80 is used when osteoporosis IS associated with a current pathological fracture. A pathological fracture is a break in a bone that is diseased (weakened) and therefore breaks with minimal or no trauma.
- M81 is used when osteoporosis exists but there is NO current pathological fracture.
- A code from M80, not a traumatic fracture code, should be used for any patient with known osteoporosis who suffers a fracture, even if the patient had a minor fall or trauma, if that fall or trauma would not ordinarily have caused a fracture in a non-diseased bone.
Guideline 2: 7th Character Requirements for M80
Codes in subcategory M80 require a 7th character to indicate the episode of care:
| 7th Character | Meaning | Clinical Context |
|---|---|---|
| A | Initial encounter for fracture | Active treatment: casting, surgery, ED/urgent care visit, first outpatient encounter while fracture is receiving active treatment |
| D | Subsequent encounter for fracture with routine healing | Fracture is healing normally; follow-up cast changes, hardware adjustments, orthopedic F/U |
| G | Subsequent encounter for fracture with delayed healing | Healing is not progressing as expected; delayed union |
| K | Subsequent encounter for fracture with nonunion | Fracture failed to unite; pseudoarthrosis |
| P | Subsequent encounter for fracture with malunion | Fracture healed in abnormal position |
| S | Sequela | Complications or conditions that arise as a direct result of a healed fracture (e.g., post-fracture kyphosis, chronic pain from old VCF) |
Guideline 3: Site and Laterality
Many M80 codes require a 6th character for site and laterality:
- The site identifies the specific bone or region (shoulder, humerus, forearm, hand, femur/hip, lower leg, ankle/foot, vertebra)
- Laterality is required for limb fractures (1=right, 2=left, 9=unspecified)
- Vertebral osteoporotic pathological fractures are coded to M80.08X- when the provider documents vertebra(e); use the applicable 7th character for the encounter and verify any more specific FY 2027 site code in the Tabular List when another site, such as pelvis or other site, is documented
Guideline 4: Sequencing — Primary vs. Secondary Osteoporosis
- When osteoporosis is due to an underlying condition or drug therapy, assign the osteoporosis code that matches the presence or absence of a current pathological fracture and add codes for the documented cause, drug exposure, or adverse effect as directed by the Tabular List. Do not state a blanket etiology/manifestation sequencing rule for all secondary osteoporosis cases; sequence according to the reason for encounter and applicable Tabular notes.
- Examples: Long-term steroid use (Z79.52) → M81.8; Cushing’s disease (E24.0) → M81.8; Hyperparathyroidism (E21.0) → M81.8
- Exception: When the encounter is for the fracture itself, M80.8xx may be sequenced as the principal/first-listed diagnosis.
Guideline 5: Personal History vs. Current Fracture
- Z87.310 (personal history of healed osteoporosis fracture) is used ONLY when the fracture has healed and is no longer under active treatment. This code does NOT map to an HCC.
- When a patient is still receiving care for an osteoporotic fracture, M80.x with the appropriate 7th character (D, G, K, P) is correct — not Z87.310.
Guideline 6: MS-DRG Assignment
Osteoporotic fractures assigned to the appropriate M80 codes will map to MS-DRGs based on the fracture site and complications:
- Hip/femur fracture (M80.051xA–M80.062xA): MS-DRG 480–482 (Hip & Femur Procedures) when surgical; MS-DRG 536–538 (Fractures of Hip & Pelvis) when non-surgical
- Vertebral fracture (M80.0AxA): MS-DRG 551–553 (Medical Back Problems)
- Presence of MCC/CC significantly affects DRG weight and reimbursement
FY2023/FY2024 restructuring note: CMS expanded the M80 subcategory in FY2023 to add more granular vertebral fracture site codes (M80.0A–M80.0B series for specific cervical and thoracic levels). For FY2026, verify updated code assignments at CMS ICD-10-CM tabular for the most current valid codes. The M80.0Xx placeholder codes remain valid when site-specific information is not documented.
🔢 ICD-10-CM Code Set (Tabular)
M80 — Osteoporosis with Current Pathological Fracture
| Code | Description | Notes / 7th Char Required |
|---|---|---|
| M80.00xA | Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter | Use when site not documented; add A/D/G/K/P/S |
| M80.011A | Age-related osteoporosis w/ current pathological fracture, right shoulder, initial encounter | Includes right shoulder/upper arm area |
| M80.012A | Age-related osteoporosis w/ current pathological fracture, left shoulder, initial encounter | |
| M80.021A | Age-related osteoporosis w/ current pathological fracture, right humerus, initial encounter | |
| M80.022A | Age-related osteoporosis w/ current pathological fracture, left humerus, initial encounter | |
| M80.031A | Age-related osteoporosis w/ current pathological fracture, right forearm, initial encounter | Includes distal radius (Colles’ fracture) |
| M80.032A | Age-related osteoporosis w/ current pathological fracture, left forearm, initial encounter | |
| M80.041A | Age-related osteoporosis w/ current pathological fracture, right hand, initial encounter | |
| M80.042A | Age-related osteoporosis w/ current pathological fracture, left hand, initial encounter | |
| M80.051A | Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture | Hip/femur fracture; V28 HCC 402 (Hip Fracture/Dislocation), initial encounter |
| M80.052A | Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture | Hip/femur fracture; V28 HCC 402 (Hip Fracture/Dislocation), initial encounter |
| M80.061A | Age-related osteoporosis w/ current pathological fracture, right lower leg, initial encounter | |
| M80.062A | Age-related osteoporosis w/ current pathological fracture, left lower leg, initial encounter | |
| M80.071A | Age-related osteoporosis w/ current pathological fracture, right ankle and foot, initial encounter | |
| M80.072A | Age-related osteoporosis w/ current pathological fracture, left ankle and foot, initial encounter | |
| M80.0AXA | Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture | Use when the osteoporotic pathological fracture site is documented but not represented by the more specific site categories; verify the required 7th character in the FY2027 Tabular List |
| M80.08xA | Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture | Vertebral compression fracture; use the appropriate 7th character for initial, subsequent healing status, or sequela |
| M80.0B1A–M80.0B9A | Age-related osteoporosis with current pathological fracture, pelvis, initial encounter for fracture (right/left/unspecified pelvis) | FY2027 valid pelvic fracture codes include right pelvis, left pelvis, and unspecified pelvis; add the appropriate 7th character for the encounter |
| M80.80xA | Other osteoporosis with current pathological fracture, unspecified site, initial encounter | Secondary osteoporosis with fracture; use with underlying cause code |
| M80.811A–M80.812A | Other osteoporosis w/ current pathological fracture, shoulder (right/left), initial encounter | Secondary osteoporosis fracture |
| M80.851A–M80.852A | Other osteoporosis w/ current pathological fracture, femur (right/left), initial encounter | Secondary osteoporosis hip fracture |
| M80.88xA | Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture | Secondary or non-age-related osteoporosis with vertebral pathological fracture; use the appropriate 7th character for initial, subsequent healing status, or sequela |
M81 — Osteoporosis without Current Pathological Fracture
| Code | Description | Notes |
|---|---|---|
| M81.0 | Age-related osteoporosis without current pathological fracture | Primary diagnosis when DXA T-score ≤ −2.5 and no current fracture; most common code; no HCC mapping |
| M81.6 | Localized osteoporosis [Lequesne] | Regional (transient) osteoporosis; often affects hip in younger adults; distinguish from systemic osteoporosis |
| M81.8 | Other osteoporosis without current pathological fracture | Secondary osteoporosis without fracture; code underlying cause first (steroid use, hyperparathyroidism, etc.) |
Related / Additional Codes (Assign with M80/M81 as appropriate)
| Code | Description | When to Use |
|---|---|---|
| Z87.310 | Personal history of (healed) osteoporosis fracture | Past osteoporotic fracture, now healed; no active treatment; no HCC |
| Z79.83 | Long-term (current) use of bisphosphonates | Code in addition to osteoporosis when on alendronate, risedronate, zoledronic acid, ibandronate |
| Z79.52 | Long-term (current) use of systemic steroids | When on prednisone, methylprednisolone systemically; supports secondary osteoporosis coding |
| Z79.51 | Long-term (current) use of inhaled steroids | Minor fracture risk; code when documented; typically insufficient alone for secondary osteoporosis |
| Z13.820 | Encounter for screening for osteoporosis | Asymptomatic screening DXA visit; first-listed code for screening encounter |
| Z79.818 | Long-term (current) use of other medications | Use for aromatase inhibitors (letrozole, anastrozole) prescribed for breast cancer — significant osteoporosis risk |
| M85.80 | Other specified disorders of bone density and structure, unspecified site | Osteopenia (T-score −1.0 to −2.5) when specifically documented as low bone density — not osteoporosis |
| M85.88 | Other specified disorders of bone density and structure, other site | Site-specific osteopenia documentation |
| E55.9 | Vitamin D deficiency, unspecified | Common comorbidity; contributes to secondary osteoporosis and fracture risk; always code when documented |
| E83.51 | Hypocalcemia | Low serum calcium; may be secondary to vitamin D deficiency or hypoparathyroidism |
| E21.0 | Primary hyperparathyroidism | Underlying cause of secondary osteoporosis; sequence before M81.8 |
| E21.1 | Secondary hyperparathyroidism, NEC | Often due to vitamin D deficiency or CKD; code CKD (N18.x) if applicable |
| E21.3 | Hyperparathyroidism, unspecified | Use when type not specified |
| E22.0 | Acromegaly and pituitary gigantism | GH excess → secondary osteoporosis; sequence before M81.8 |
| E23.0 | Hypopituitarism | Includes growth hormone deficiency → bone loss in adults |
| E24.0 | Pituitary-dependent Cushing’s disease | Glucocorticoid excess from pituitary adenoma → osteoporosis; sequence before M81.8 |
| E24.9 | Cushing’s syndrome, unspecified | When Cushing’s type not specified |
| E27.1 | Primary adrenocortical insufficiency (Addison’s disease) | Cortisol deficiency; steroid replacement may contribute to osteoporosis if over-replaced |
| E28.310 | Symptomatic premature menopause | Premature ovarian failure causing early estrogen loss → osteoporosis risk; sequence before M81.8 |
| E28.319 | Asymptomatic premature menopause | Same as above; no symptoms but early menopause documented |
| E28.39 | Other primary ovarian failure | Including chemotherapy-induced ovarian failure (POF) |
| E89.40 | Asymptomatic postsurgical ovarian failure | Surgical menopause → accelerated bone loss; code before M81.8 |
| E89.41 | Symptomatic postsurgical ovarian failure | Surgical menopause with symptoms; significant osteoporosis risk |
| K50.x | Crohn’s disease | IBD-associated bone loss from malabsorption and systemic inflammation; code before M81.8 |
| K51.x | Ulcerative colitis | UC-associated bone loss; steroid treatment further compounds risk |
| K90.0 | Celiac disease | Malabsorption of calcium and vitamin D → secondary osteoporosis; code before M81.8 |
| N18.3–N18.6 | Chronic kidney disease, stage 3–5 | Renal osteodystrophy component; CKD-MBD; refer to Renal CDG; code before M81.8 |
| M32.10 | Systemic lupus erythematosus, organ/system involvement unspecified | SLE-associated osteoporosis from steroids and disease activity |
| G35 | Multiple sclerosis | Immobility + steroid treatment → secondary osteoporosis |
| M84.4xx | Pathological fracture NEC | Pathologic fracture NOT due to osteoporosis (use when underlying bone disease is NOT osteoporosis) |
| M84.5xx | Pathological fracture in neoplastic disease | Fracture in bone metastasis or primary bone tumor; requires neoplasm code as well |
| M84.6xx | Pathological fracture in other disease | Fracture due to Paget’s, osteomyelitis, or other bone disease — not osteoporosis |
| N95.1 | Menopausal and female climacteric states | Menopause-associated symptoms in a patient with age-related osteoporosis |
| G89.18 | Other acute postprocedural pain | Pain following vertebroplasty/kyphoplasty procedure when not healing-related |
Do not use M84.4xx for osteoporotic fractures. M84.40–M84.48 are reserved for pathological fractures due to causes OTHER than osteoporosis (e.g., osteogenesis imperfecta, Paget’s disease). When the underlying cause is osteoporosis specifically, the correct code family is M80.x. Misuse of M84.4xx for osteoporotic fractures misstates the etiology and may trigger claims review. Under V28, M80.08XA maps to HCC 401, while M84.48XA maps to no HCC.
🔎 Indexing
The following alphabetic index entries from the FY2027 ICD-10-CM Alphabetic Index assist in locating the correct osteoporosis code:
| Index Entry (Term) | Subterm | Code Result |
|---|---|---|
| Osteoporosis | (main term) | See subcategory M81 |
| Osteoporosis | with current pathological fracture | M80.00x– |
| Osteoporosis | age-related (senile) | M81.0 |
| Osteoporosis | age-related, with current pathological fracture | M80.00x– |
| Osteoporosis | disuse | M81.8 |
| Osteoporosis | drug-induced | M81.8 |
| Osteoporosis | idiopathic | M81.8 |
| Osteoporosis | localized (Lequesne) | M81.6 |
| Osteoporosis | postmenopausal | M81.0 |
| Osteoporosis | postoophorectomy (postsurgical) | M81.8 (with E89.4x first) |
| Osteoporosis | secondary NEC | M81.8 |
| Fracture, pathological | in osteoporosis | M80.00x– |
| Fracture, pathological | osteoporosis, age-related — see Osteoporosis, with current pathological fracture | M80.0xx– |
| Fracture, vertebra(e) | pathological — in osteoporosis | M80.08x– |
| History, personal | fracture, osteoporosis (healed) | Z87.310 |
| Screening | osteoporosis | Z13.820 |
| Bone density, low | (osteopenia) | M85.8x |
Placeholder “X” characters: Many M80 codes require placeholder “X” characters to reach the required 7th character position. For example, M80.00XA — the “X” is a placeholder (6th character) that must be present before the 7th character “A.” Omitting placeholder characters will result in an invalid code on claims. Always verify code validity in the FY2027 Tabular List.
🏥 CPT
| CPT Code | Description | Global / Setting | Notes |
|---|---|---|---|
| 77080 | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine) | XXX / Outpatient | Standard DXA; Medicare-covered every 2 years (more frequently if documented clinical need); primary screening and monitoring code. Requires ICD-10 Z13.820 (screening) or M81.0 (established osteoporosis) |
| 77081 | DXA, bone density study, 1 or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel) | XXX / Outpatient | Peripheral DXA; lower clinical utility than 77080; may be used in office settings with peripheral DXA devices |
| 77085 | DXA bone density study, including vertebral fracture assessment | XXX / Outpatient | Combined bone density + VFA (lateral spine imaging for VCF detection); preferred when VCF suspected; higher reimbursement than 77080 alone |
| 77086 | Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA) | XXX / Outpatient | Stand-alone VFA via DXA; do not report with 77080 or 77085 |
| 76977 | Ultrasound, bone density measurement and interpretation, peripheral site(s), any method | XXX / Outpatient | US bone density (heel/calcaneus); not a Medicare-covered DXA equivalent; use for initial risk stratification only |
| 0554T–0558T | Quantitative computed tomography (QCT) bone mineral density measurement (Category III) | XXX / Outpatient | QCT scan of spine or hip; 3D volumetric BMD; not DXA equivalent for Medicare; Category III tracking codes; may be reported at institutions performing QCT |
| 22510 | Percutaneous vertebroplasty, any method, including fluoroscopic guidance; cervical or thoracic | 000 / Outpatient or Inpatient | Cement injection into fractured vertebra; used for painful osteoporotic VCF unresponsive to conservative care |
| 22511 | Percutaneous vertebroplasty; lumbar | 000 | Lumbar vertebroplasty; code per level (add-on 22512 for additional levels) |
| 22513 | Percutaneous vertebral augmentation, including cavity creation (kyphoplasty), any method; thoracic | 000 | Balloon kyphoplasty: creates cavity with balloon, then fills with cement; reduces kyphosis compared to vertebroplasty |
| 22514 | Percutaneous vertebral augmentation (kyphoplasty); lumbar | 000 | Lumbar kyphoplasty; add-on 22515 for each additional level |
| 22515 | Percutaneous vertebral augmentation; each additional thoracic or lumbar vertebral body (add-on) | ZZZ | Add-on to 22513 or 22514 for multi-level procedures |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 000 / Office | Used for SC administration of denosumab (Prolia), teriparatide (Forteo), abaloparatide (Tymlos), romosozumab (Evenity) in office; report with appropriate J-code |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 000 / Office/Outpatient | Use for IV zoledronic acid (Reclast) infusion when the infusion administration service is separately reportable; report the drug with J3489 and document infusion start/stop time per payer policy |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | ZZZ | If a nonchemotherapy zoledronic acid infusion extends beyond the initial hour and payer time requirements are met; rarely needed for osteoporosis dosing |
| 96160 | Administration of patient-focused health risk assessment instrument, with scoring and documentation, per standardized instrument | 000 / Office | May apply to a separately reportable standardized patient-focused risk assessment when payer policy supports reporting; do not use deleted CPT 99420 |
Medicare DXA coverage (77080): Medicare Part B covers DXA (77080) every 24 months for beneficiaries who meet risk criteria per CMS NCD 150.3. More frequent scanning is covered when results will affect management decisions. Ensure the diagnosis code supports medical necessity — Z13.820 for screening, M81.0 or M80.x for monitoring established disease, or appropriate risk-factor codes (N95.1, Z79.52, E21.0, etc.) for at-risk patients.
🧾 HCPCS
| HCPCS Code | Description | Typical Use / Notes |
|---|---|---|
| J0897 | Injection, denosumab, 1 mg (Prolia / Xgeva) | Prolia 60 mg = 60 units (J0897 × 60) SC q6 months for osteoporosis. Part B-covered when administered in physician office/outpatient facility. Medicare reimbursement at ASP + 6%. Do not confuse with Xgeva (oncology indication — different dose/frequency) |
| J3489 | Injection, zoledronic acid, 1 mg | Reclast 5 mg = 5 units (J3489 × 5) IV annually for osteoporosis when medically necessary and covered. Annual dosing; used in patients unable to tolerate oral bisphosphonates or meeting payer criteria |
| J3110 | Injection, teriparatide, 10 mcg (Forteo) | Forteo 20 mcg/day SC = 2 units/day; billed per administration in office (home administration covered under Part D). Used for severe osteoporosis or treatment failure. Verify current descriptor for FY2026; may be J-code reassigned |
| J3590 | Unclassified biologics | Abaloparatide (Tymlos) does not have a standard osteoporosis-specific J-code in the cited CMS home-health billing guidance; CMS instructs use of J3590 for abaloparatide in that context. Verify current HCPCS, payer policy, route, NDC, and setting before billing. |
| J1740 | Injection, ibandronate sodium, 1 mg | Boniva IV 3 mg = 3 units (J1740 × 3) every 3 months when medically necessary and covered. Do not report J3489 for ibandronate; J3489 is zoledronic acid |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Evenity 210 mg = 210 units (J3111 × 210) when separately payable and covered. Requires documentation of drug name, dose, route, NDC, indication, and payer coverage requirements |
| G0108 | Diabetes outpatient self-management training (DSMT) — individual | Not osteoporosis-specific but may be used in conjunction in patient with diabetic osteoporosis; listed for completeness |
| Q9977 | Compounded drug — not applicable unless compounded bisphosphonate used | Non-standard; document thoroughly if applicable |
The charge capture system shows J0897 (denosumab/Prolia) billed in the physician office, but the diagnosis on the claim is M81.0 (osteoporosis without fracture). Review: Is there documentation supporting current pathological fracture that would change the diagnosis to M80.x? Also confirm: Is the patient on long-term systemic steroids (Z79.52) suggesting secondary osteoporosis (M81.8)? Accurate diagnosis coding on the injection claim is required for clean claims and audit defense.
📚 AHA Coding Clinic
The following AHA Coding Clinic guidance is relevant to osteoporosis coding. Coders should verify the most current issue for any updates:
| Topic | Coding Clinic Reference | Key Guidance |
|---|---|---|
| Pathological fracture vs. traumatic fracture in osteoporosis | AHA Coding Clinic, 2Q 2018, “Osteoporosis and Fracture (Traumatic versus Pathologic)”; ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.13.d.2 | A code from category M80, not a traumatic fracture code, should be used for any patient with known osteoporosis who suffers a fracture, even if the patient had a minor fall or trauma, if that fall or trauma would not usually break a normal, healthy bone. When the documentation is unclear, query the provider: if an osteoporotic pathologic fracture is confirmed, assign M80.051A (example: right femur); if the provider documents the fracture was due to trauma from the fall, assign the traumatic fracture code (for example, S72.301A). |
| Sequencing: secondary osteoporosis with fracture | ICD-10-CM Tabular List FY 2027, subcategory M80.8-; ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.21.c.3 | Drug-induced osteoporosis with current pathological fracture is classified to subcategory M80.8-, Other osteoporosis with current pathological fracture. Sequence according to the reason for the encounter, and use an additional code for adverse effect to identify the drug (T36-T50 with fifth or sixth character 5), for example T38.0X5A for glucocorticoids. Z79.52, Long term (current) use of systemic steroids, may be added when the patient is on long-term steroid therapy. |
| Osteoporosis documentation requirement | AHA Coding Clinic, 1Q 2013, “Using the X-ray Report for Specificity”; ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Sections III.B and IV.K | In the inpatient setting, abnormal findings (laboratory, x-ray, and other diagnostic results, such as a DXA T-score) are not coded unless the provider indicates their clinical significance; if the provider has ordered further tests or treatment, ask whether the finding should be added. A diagnostic report may add specificity only to a condition the provider has already diagnosed. For outpatient encounters for diagnostic tests interpreted by a physician, code any confirmed or definitive diagnosis documented in the interpretation. Assign M81.0 when age-related osteoporosis without current pathological fracture is diagnosed. |
| Personal history of osteoporotic fracture (Z87.310) | ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Sections I.C.13.c and I.C.13.d.1 | Category M81 is for patients with osteoporosis who do not currently have a pathologic fracture, even if they had a fracture in the past; Z87.310, Personal history of (healed) osteoporosis fracture, should follow the M81 code. While the fracture is current, use M80 with 7th character A during active treatment, D for routine care during healing or recovery, and the other 7th characters (G, K, P, S) for delayed healing, nonunion, malunion, or sequela. |
| Vertebral compression fracture: finding on imaging vs. acute fracture | ICD-10-CM Tabular List FY 2027, codes M80.08XA, Z87.310 and M48.5- Excludes1 note; ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.13.b | A current osteoporotic vertebral fracture is coded M80.08XA (age-related osteoporosis, initial encounter for fracture). A healed vertebral collapse due to osteoporosis is coded Z87.310, which includes personal history of (healed) collapsed vertebra due to osteoporosis. M48.5-, Collapsed vertebra NEC, excludes pathological fracture of vertebra due to osteoporosis (M80.-) and traumatic fracture of vertebra (S12.-, S22.-, S32.-). When imaging does not establish whether the fracture is current, query the provider. |
| Glucocorticoid-induced osteoporosis (GIOP) | AHA Coding Clinic guidance on adverse effects of medications | Steroid-induced osteoporosis is coded as adverse effect (not poisoning/underdosing) when the steroid is taken as prescribed. Code M81.8 (secondary osteoporosis) + Z79.52 (long-term steroid use). The steroid use code does not replace an adverse effect T-code unless the dosing pattern is itself at issue. |
💰 HCC / Risk Adjustment
Osteoporosis itself maps to no V28 payment HCC; only the related hip/femur or vertebral fracture, at an initial encounter, maps. Mappings below follow the 2024 CMS-HCC model (commonly called V28), which CMS uses at 100 percent for non-PACE Medicare Advantage risk scores and continued for CY 2027, and the CMS 2027 Initial ICD-10-CM Mappings. Coefficients vary by enrollee segment and payer, so this guide does not quote RAF weights; check the current CMS model software. Hierarchies are applied by CMS after coding: code every documented, supported condition.
| ICD-10-CM Code(s) | Description | V28 HCC | Coding / Documentation Notes |
|---|---|---|---|
| M81.0, M81.6, M81.8 | Age-related osteoporosis without current pathological fracture; localized; other | No V28 payment HCC | Code with Z87.310 for a healed osteoporotic fracture |
| M80.051A–M80.059A | Age-related osteoporosis with current pathological fracture, femur, initial encounter | HCC 402 — Hip Fracture/Dislocation | — |
| M80.08XA | Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter | HCC 401 — Vertebral Fractures without Spinal Cord Injury | — |
| M80.0-, M80.8- with 7th character D, G, K, P, or S | Same, subsequent encounter or sequela | No V28 payment HCC | — |
| M80.0- other sites (humerus, forearm, hand, lower leg, ankle, other site), initial encounter | Osteoporotic pathological fracture, other sites | No V28 payment HCC | — |
| E24.0 | Pituitary-dependent Cushing’s disease (secondary cause) | HCC 51 — Addison’s and Cushing’s Diseases, Acromegaly, and Other Endocrine and Metabolic Disorders | E21.0 and E24.9 map to no HCC |
| N18.4, N18.5 | Chronic kidney disease, stage 4; stage 5 | HCC 327; HCC 326 | — |
V24 HCC 169 and the label “HCC 171” are retired. Pathological vertebral fractures coded to M84.48XA, M84.58XA, or M84.68XA map to no HCC; only M80.08XA and M48.5-XA map to HCC 401.
The note must show the fracture is being actively treated at that encounter (imaging, bracing, surgery, or a new treatment plan) to support an initial-encounter 7th character. A history of an osteoporotic fracture with ongoing osteoporosis management is M81.0 with Z87.310.
Sources: CMS 2027 Initial ICD-10-CM Mappings (2024 CMS-HCC model, V28); CMS CY 2024 Rate Announcement, Attachment VI (labels, hierarchies); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines. Verified November 3, 2026.
✍️ CDI Query Templates
All query templates below follow ACDIS/AHIMA query guidelines: non-leading, multiple-choice format, with clinical context provided.
| Scenario | Clinical Context to Include in Query | Suggested Query Wording (Multiple Choice) |
|---|---|---|
| Osteoporosis not documented despite DXA T-score ≤ −2.5 and bisphosphonate therapy | DXA date, T-score value, current medications (alendronate, etc.) | “Based on the documented DXA T-score of [value] and current bisphosphonate therapy, can you please clarify the patient’s bone health diagnosis? Options: (1) Osteoporosis; (2) Osteopenia/Low bone mass; (3) Normal bone density; (4) Undetermined; (5) Other: ___” |
| Vertebral compression fracture — pathologic vs. traumatic etiology unclear | Imaging findings, mechanism of injury, age, prior DXA, mechanism energy level | “The imaging shows a vertebral compression fracture. Based on your clinical assessment, what is the primary etiology of this fracture? Options: (1) Pathological fracture due to osteoporosis (M80.08XA for initial encounter when vertebra[e] is the documented site); (2) Traumatic fracture due to injury mechanism (S-code); (3) Pathological fracture due to metastatic disease (M84.5xx); (4) Pathological fracture due to other bone disease; (5) Undetermined; (6) Other: ___” |
| Hip fracture in elderly patient — osteoporosis not documented | Age, mechanism (fall from standing height), prior fracture history, imaging | “This patient is [age] and sustained a hip fracture following a fall from standing height. Can you clarify whether the patient has a diagnosis of osteoporosis? Options: (1) Yes — age-related osteoporosis (M81.0 / M80.05xA); (2) Yes — secondary osteoporosis (specify cause: ___); (3) No — traumatic fracture; (4) Undetermined at this time; (5) Other: ___” |
| Long-term steroid use documented but secondary osteoporosis not stated | Steroid medication, dose, duration (Z79.52 in chart), imaging or DXA findings | “This patient has been on systemic corticosteroids ([drug, dose]) for [duration]. Given this and the documented [DXA result/fracture], can you clarify whether the patient has a diagnosis of steroid-induced (secondary) osteoporosis? Options: (1) Yes — secondary osteoporosis due to glucocorticoid use; (2) Yes — age-related osteoporosis (co-existing, not steroid-induced); (3) Osteopenia only; (4) No osteoporosis; (5) Undetermined; (6) Other: ___” |
| Secondary osteoporosis — underlying cause undocumented | Lab values (PTH, cortisol, TSH), diagnoses (CKD, celiac, IBD, malignancy on aromatase inhibitors) | “Documentation indicates osteoporosis is present. Can you clarify whether this osteoporosis is: (1) Age-related/primary; (2) Secondary to hyperparathyroidism (E21.x); (3) Secondary to malabsorption/IBD/celiac disease; (4) Secondary to chronic kidney disease; (5) Secondary to hormonal deficiency (premature menopause/postsurgical); (6) Secondary to Cushing’s syndrome; (7) Secondary to other cause: ___; (8) Undetermined?” |
| Osteoporotic fracture — fracture site specificity needed for coding laterality | Imaging report showing specific fracture site (right vs. left, bone level) | “Imaging shows a fracture of the [site]. Can you confirm whether this is on the right side, left side, or bilateral? This information is needed for accurate ICD-10 coding. Right / Left / Bilateral / Undetermined.” |
Risk Adjustment / RAF capture opportunity: A Medicare Advantage patient presents for follow-up of “known osteoporosis.” The chart documents back pain and refers to a “prior compression fracture” but does not specify if it is currently healing or fully healed. If the vertebral fracture is still undergoing treatment (pain management, physical therapy, bracing), the correct code family is M80.08XD (subsequent encounter for fracture with routine healing, when documented as vertebra[e]) and maps to no V28 payment HCC; only the initial-encounter code M80.08XA maps to HCC 401 (CMS 2027 Initial ICD-10-CM Mappings). If fully healed with no ongoing treatment, Z87.310 applies (no HCC). Query the provider for current fracture status.
🧑⚕️ Treatments (Clinical)
Clinical management of osteoporosis is multifaceted, incorporating lifestyle modification, pharmacological therapy, and fracture prevention strategies. Per Endocrine Society 2019 guidelines and updated NOF treatment guidelines:
Non-Pharmacological Interventions
- Fall prevention programs: Balance training (e.g., tai chi), physical therapy, home safety assessment, footwear optimization, vision correction — directly reduces fracture incidence.
- Weight-bearing and resistance exercise: 30 minutes most days; improves BMD modestly, improves muscle strength and proprioception significantly.
- Calcium and Vitamin D optimization: Dietary calcium 1,000–1,200 mg/day; Vitamin D 800–1,000 IU/day for adults ≥ 50; serum 25-OH Vitamin D target ≥ 30 ng/mL.
- Smoking cessation: Smoking directly accelerates bone loss (estimated −3% to −5% BMD loss at hip).
- Alcohol reduction: Limit to < 2 drinks/day; alcohol increases fall risk and impairs bone formation.
- Vertebral augmentation (vertebroplasty / kyphoplasty): For painful osteoporotic VCF unresponsive to ≥ 4–6 weeks conservative management; CPT 22510–22515. NASS guidelines support kyphoplasty for acute painful VCF.
- Hip protectors: Padded undergarments that absorb hip impact; evidence mixed for community-dwelling patients but supported for high-risk nursing home residents.
Pharmacological Treatment Thresholds
Per NOF, pharmacotherapy is recommended when:
- DXA T-score ≤ −2.5 at lumbar spine or hip
- DXA T-score between −1.0 and −2.5 (osteopenia) plus FRAX 10-year hip fracture probability ≥ 3% OR major osteoporotic fracture probability ≥ 20%
- Any prior hip or vertebral fracture (regardless of T-score)
Monitoring
- Repeat DXA every 1–2 years to monitor treatment response; significant change defined as ≥ 3–5% change (exceeds least significant change for the machine)
- Bone turnover markers (CTX, P1NP) can be used at 3–6 months to confirm pharmacological response
- Drug holidays (bisphosphonates): After 3–5 years of oral bisphosphonate or 3 years IV zoledronic acid, reassess fracture risk; low-risk patients may take a drug holiday (stop therapy) while monitoring continues
- Rare but serious complications to monitor: Atypical femoral fracture (AFF) — code from M84.75- with required specificity and 7th character; Osteonecrosis of the jaw (ONJ) — M87.180 when documented as drug-induced — associated with long-term bisphosphonate or denosumab use
🎓 Patient Education / Summary
The following summary is intended to assist CDI and clinical staff in patient education, reinforcing documentation accuracy and care coordination for osteoporosis management:
Key Facts for Patients and Families
- Osteoporosis is preventable and treatable. Early diagnosis through DXA screening, combined with medication and lifestyle changes, can significantly reduce fracture risk.
- Who should be screened: Per USPSTF guidelines: all women age 65 and older; postmenopausal women under 65 who are at increased fracture risk based on formal clinical risk assessment. For men, USPSTF finds evidence insufficient to determine the balance of benefits and harms; screening decisions should be individualized, especially when risk factors or secondary causes are present. Code Z13.820 for an osteoporosis screening encounter.
- DXA scan information: The DXA (bone density test) is a low-radiation X-ray that measures bone mineral density. Scores are reported as T-scores. A T-score of −2.5 or lower means osteoporosis.
- Medication adherence is critical: Oral bisphosphonates (alendronate, risedronate) must be taken correctly — on an empty stomach, with a full glass of water, remain upright for 30 minutes — to be effective and minimize esophageal irritation.
- Do not stop denosumab (Prolia) without talking to your doctor. Stopping this medicine suddenly can cause multiple spinal fractures. A different bone medicine must be started when stopping Prolia.
- Fall prevention is as important as medication. Most osteoporotic fractures are caused by falls. Remove home hazards, use grab bars, ensure adequate lighting, and review all medications that cause dizziness.
- Vitamin D and Calcium: Many patients with osteoporosis are deficient in vitamin D and calcium. These should be measured and replaced as needed — lab testing supports E55.9 or E83.51 coding when deficiencies are present.
Documentation Reminders for Clinical Staff
- Always document “osteoporosis” explicitly in the assessment/plan when a DXA T-score ≤ −2.5 or a fragility fracture is present — do not rely on lab/radiology reports alone.
- Specify fracture site and laterality (right vs. left) for all pathological fractures — this affects ICD-10 code assignment and HCC capture.
- Note whether a fracture is new (initial encounter, 7th char A), healing (subsequent, 7th char D), or the old fracture is now a sequela (7th char S).
- Document underlying causes of secondary osteoporosis (steroids, hyperparathyroidism, malabsorption, hormonal deficiency) — these support additional codes and may have independent HCC value.
- Document Vitamin D and calcium levels if tested — supports clinical coding of deficiency conditions.
Coding Summary
| Clinical Scenario | Primary ICD-10-CM Code(s) | Additional Codes |
|---|---|---|
| Osteoporosis (DXA confirmed), no fracture, age-related | M81.0 | Z79.83 (if on bisphosphonate) |
| Osteoporosis with acute vertebral compression fracture (initial encounter) | M80.08xA | Z79.83 or Z79.52; G89.18 if acute pain coded |
| Osteoporosis with hip fracture (initial encounter, right) | M80.051A | Z79.83 or J0897 (if on Prolia) |
| Steroid-induced (secondary) osteoporosis, no fracture | M81.8 | Z79.52 |
| Secondary osteoporosis with pathological fracture due to steroid use | M80.80xA or site-specific M80.8xxA | Z79.52 |
| Osteoporosis screening encounter (asymptomatic) | Z13.820 | N95.1 (if menopausal) or Z79.52 (if steroid risk factor) |
| Personal history of healed osteoporotic fracture | Z87.310 | M81.0 (current osteoporosis if still present) |
| Osteopenia (T-score −1.0 to −2.5), no fracture | M85.80 or M85.88 (site-specific) | Z13.820 if screening; E55.9 if vit D deficient |
| Hyperparathyroidism causing secondary osteoporosis with fracture | E21.0 + M80.80xA | Z79.83; E55.9 if vitamin D deficient |
| Vertebral fracture follow-up — fracture healing normally | M80.08xD | Continues to support current fracture risk-adjustment capture when documented and supported (e.g., HCC 401 in the 2027 CDI Reference) |
Always verify codes in the FY2027 ICD-10-CM Official Tabular List before finalizing a claim. The M80 category includes site-specific codes for osteoporosis with current pathological fracture, and 7th characters are required to report the episode of care and healing status. Confirm that any placeholder “X” characters are correctly placed and that the 7th character is appropriate. Codes without required characters (e.g., M80.08 without the 7th character) are invalid and will be rejected on claims.
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026) and CPT/HCPCS 2027, except where payer-specific policies require separate verification. All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
CCO Hero
Know someone starting a medical coding career?
Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.
Become a CCO Hero